entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 13:17:14 - browse：5252

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Ambulance rides for just $100? Advisers want major billing fixes

knowledge

WSS

Extreme heat events are a public health emergency

Excited delirium, Elijah McClain, and emergency physicians

Medicare solvency divides Republicans at the presidential debate

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

FDA approves Recor Medical high blood pressure device

U.K. considers world's first use of meningitis vaccine to address gonorrhea

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Anthos stroke drug appears safer than common blood thinner

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Medicare proposal to cover medical devices draws a mixed reaction

Extreme heat events are a public health emergency

Medical leaders decry Supreme Court decision on affirmative action

Diversify hospital leadership teams to protect BIPOC patient health

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

hotspot

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Anthos stroke drug appears safer than common blood thinner

Victims of gun violence feel impacts long after bullet wound

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Congress must reauthorize a committee to support older Americans

Weight loss drug costs may need more research, senator suggests

Wikipedia

knowledge

explore

explore